<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418467</url>
  </required_header>
  <id_info>
    <org_study_id>EMPATHY-1</org_study_id>
    <nct_id>NCT03418467</nct_id>
  </id_info>
  <brief_title>Risk Factors in Tachycardiomyopathy</brief_title>
  <acronym>EMPATHY</acronym>
  <official_title>Evaluation of Risk Factors for Therapeutic Outcome in Patients With Tachycardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Decision between rate control and rhythm control can be a challenge in clinical practice.&#xD;
      While there is some guiding evidence, we still lack a comprehensive insight into different&#xD;
      subgroups of patients that will benefit from a rhythm control treatment.&#xD;
&#xD;
      EMPATHY is a prospective clinical study in patients presenting with heart failure and a&#xD;
      tachyarrhythmic rhythm disturbance. Biomarkers, routinely obtained results from clinical&#xD;
      examinations, and results from endomyocardial biopsies shall be evaluated to identify&#xD;
      patients which have better outcome from a rhythm control strategy by ablation therapy or, if&#xD;
      contraindicated by pharmacological rhythm control.&#xD;
&#xD;
      This study is designed to identifying risk factors and subgroups profiting from rhythm&#xD;
      restoration and therefore improve current therapeutic approaches and the rate of&#xD;
      recurrence-free survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">October 11, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>histological characteristics</measure>
    <time_frame>3 months</time_frame>
    <description>Identification of histopathological criteria, which indicate better outcome after rhythm control. Recovery of left ventricular ejection fraction (assessed by echocardiography) will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence of rhythm disturbance</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluating the recurrence of the underlying rhythm disturbance (ECG, 7 day holter monitoring, implantable event recorder)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rehospitalization</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluating the rate of unplanned rehospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluating the all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class (New York Heart Association)</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluating the extend of heart failure symptoms.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>Ventricular Premature Complexes</condition>
  <arm_group>
    <arm_group_label>tachycardiomyopathy</arm_group_label>
    <description>Sustained heart rate of over 100 bpm, exclusion of other causes of congestive heart failure including significant valvular disease and coronary artery stenosis over 50%, and partial or complete recovery of left ventricular function after restoration of sinus rhythm or rate control and characteristic histological findings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dilated cardiomyopathy</arm_group_label>
    <description>Patients with dilated cardiomyopathy according to the 2016 ESC (European Heart Association) Guidelines for the diagnosis and treatment of acute and chronic heart failure.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting at the University Hospital Tübingen with decreased left ventricular&#xD;
        ejection fraction.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newly diagnosed left ventricular ejection fraction ≤ 50%&#xD;
&#xD;
          -  endomyocardial biopsy available&#xD;
&#xD;
          -  tachycardic rhythm disturbance with a rhythm control strategy planned for tachycardic&#xD;
             atrial fibrillation or flutter (≥100/min) or more than 10000 ventricular premature&#xD;
             beats in 24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt;18 years&#xD;
&#xD;
          -  patient unable or unwilling to give informed consent&#xD;
&#xD;
          -  coronary artery stenosis &gt;50%&#xD;
&#xD;
          -  relevant valvular disease&#xD;
&#xD;
          -  simultaneous contraindications against amiodarone treatment and pulmonary vein&#xD;
             isolation/ablation therapy&#xD;
&#xD;
          -  present or suspected alcohol/drug dependency will result in exclusion from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Seizer, MD</last_name>
    <phone>0049 7071 29 83688</phone>
    <email>peter.seizer@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Heinzmann, MD</last_name>
    <phone>0049 7071 29 83688</phone>
    <email>david.heinzmann@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Medizinische Klinik III (Kardiologie)</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Seizer, MD</last_name>
      <phone>0049 7071 29 83688</phone>
      <email>peter.seizer@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>David Heinzmann, MD</last_name>
      <phone>0049 7071 29 83688</phone>
      <email>david.heinzmann@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tachycardiomyopathy</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>EMID (enrichment of mitochondria at the intercalated discs)</keyword>
  <keyword>Biopsy</keyword>
  <keyword>empathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

